43P Immunosuppressive microenvironment can be reverted by neoadjuvant chemotherapy in TNBC
Neoadjuvant chemoimmunotherapy with immune checkpoint blockers (ICBs) is the standard approach to treat early triple-negative breast cancer (TNBC). However, the pathological complete response (pCR) rate is around 65% suggesting that immunosuppressive tumor microenvironment (TME) cannot be reverted with the use of anti PD1/PDL1 immunotherapy alone. To identify patients who benefit from immunotherapy compared to those who do not and whether chemotherapy (CT) was able to revert the immunosuppressive TME, we conducetd a comprehensive analysis on a retrospective case series of tumors pre and post neo adjuvant CT (naCT) using gene expression profiling.
Authors
- Alice Indini (ORCID: https://orcid.org/0000-0001-8686-4106)
- Filippo de Braud (ORCID: https://orcid.org/0000-0003-0103-730X)
- Silvia Brich (ORCID: https://orcid.org/0000-0002-6359-1712)
- Paolo Verderio (ORCID: https://orcid.org/0000-0002-9231-1281)
- Andrea Vingiani (ORCID: https://orcid.org/0000-0002-9827-3976)
- Francesca De Santis (ORCID: https://orcid.org/0000-0001-5877-0639)
- Mara Lecchi (ORCID: https://orcid.org/0000-0002-0405-9339)
- F. Putti
- Massimo Di Nicola (ORCID: https://orcid.org/0000-0002-7689-5774)
- Giancarlo Pruneri (ORCID: https://orcid.org/0000-0002-7963-7172)
- A. Iacobucci
Institutions
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104202
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05